Toboroz
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
NCT07421167· 2. fázis· Novartis Pharmaceuticals· Forrás
Contact: Emra Kazic
Toboroz
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Contact: Astellas Pharma Global Development, Inc.
Fut, nem toboroz
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
NCT07109414· 2/3. fázis· Novita Pharmaceuticals, Inc.· Forrás
Toboroz
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· 3. fázis· Eli Lilly and Company· Forrás
Contact: Stephan Kendall (principal investigator)
Toboroz
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627· 2. fázis· Incyte Corporation· Forrás
Toboroz
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784· 3. fázis· Revolution Medicines, Inc.· Forrás
Contact: Revolution Medicines Study Director
Toboroz
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· 2/3. fázis· BioNTech SE· Forrás
Fut, nem toboroz
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
NCT06106308· 2. fázis· Cardiff Oncology· Forrás
Fut, nem toboroz
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489· 2. fázis· Shanghai Henlius Biotech· Forrás
Toboroz
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
NCT05234177· Tempus AI· Forrás
Contact: Angela Nuttall
Fut, nem toboroz
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444· Guardant Health, Inc.· Forrás
Contact: Angela Nuttall
Fut, nem toboroz
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683· 3. fázis· HUYABIO International, LLC.· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052· 3. fázis· Incyte Corporation· Forrás
Toboroz
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068· 1/2. fázis· Artios Pharma Ltd· Forrás
Contact: Sarah Cannon Development Innovations
Fut, nem toboroz
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599· 1/2. fázis· Genmab· Forrás
Fut, nem toboroz
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
NCT03816163· 2. fázis· Astellas Pharma Global Development, Inc.· Forrás
Fut, nem toboroz
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
9-ING-41 in Patients With Advanced Cancers
NCT03678883· 2. fázis· Actuate Therapeutics Inc.· Forrás
Toboroz
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835· 1/2. fázis· Genmab· Forrás
Fut, nem toboroz
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03431350· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949· 2. fázis· Partner Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
NCT02152631· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703· 3. fázis· Eli Lilly and Company· Forrás